HRP20191181T1 - 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma - Google Patents

7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma Download PDF

Info

Publication number
HRP20191181T1
HRP20191181T1 HRP20191181TT HRP20191181T HRP20191181T1 HR P20191181 T1 HRP20191181 T1 HR P20191181T1 HR P20191181T T HRP20191181T T HR P20191181TT HR P20191181 T HRP20191181 T HR P20191181T HR P20191181 T1 HRP20191181 T1 HR P20191181T1
Authority
HR
Croatia
Prior art keywords
compound
cancer agent
hydrochloride salt
butanol
hcl
Prior art date
Application number
HRP20191181TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin Stogniew
Joshua E. Allen
Bhaskara Rao Nallaganchu
Richard S. Pottorf
Gary L. Olson
Original Assignee
Oncoceutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics, Inc. filed Critical Oncoceutics, Inc.
Publication of HRP20191181T1 publication Critical patent/HRP20191181T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20191181TT 2013-03-13 2014-03-13 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma HRP20191181T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361779828P 2013-03-13 2013-03-13
US201361904718P 2013-11-15 2013-11-15
PCT/US2014/025885 WO2014160130A1 (en) 2013-03-13 2014-03-13 Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
EP14775569.8A EP2968294B1 (en) 2013-03-13 2014-03-13 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-on for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
HRP20191181T1 true HRP20191181T1 (hr) 2019-10-04

Family

ID=51527915

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191181TT HRP20191181T1 (hr) 2013-03-13 2014-03-13 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma

Country Status (26)

Country Link
US (1) US9265765B2 (enExample)
EP (2) EP2968294B1 (enExample)
JP (3) JP6446025B2 (enExample)
KR (2) KR102438135B1 (enExample)
CN (2) CN119954807A (enExample)
AU (3) AU2014244117B2 (enExample)
BR (1) BR112015023256A2 (enExample)
CA (2) CA2905037C (enExample)
CY (1) CY1121735T1 (enExample)
DK (1) DK2968294T3 (enExample)
EA (1) EA037937B1 (enExample)
ES (1) ES2734568T3 (enExample)
HR (1) HRP20191181T1 (enExample)
HU (1) HUE044238T2 (enExample)
IL (2) IL241452B (enExample)
LT (1) LT2968294T (enExample)
ME (1) ME03470B (enExample)
MX (2) MX2015012636A (enExample)
NZ (2) NZ711948A (enExample)
PL (1) PL2968294T3 (enExample)
PT (1) PT2968294T (enExample)
RS (1) RS59013B1 (enExample)
SG (2) SG11201507247WA (enExample)
SI (1) SI2968294T1 (enExample)
SM (1) SMT201900384T1 (enExample)
WO (1) WO2014160130A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
HRP20191181T1 (hr) 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
LT2970473T (lt) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
PL3068401T3 (pl) * 2013-11-15 2019-08-30 Oncoceutics, Inc. 7-Benzylo-4-(2-metylobenzylo)-2,4,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn- 5(1H)-on, jego sole i sposoby zastosowania
CN106687125B (zh) 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
KR102611067B1 (ko) * 2014-03-31 2023-12-06 더 스크립스 리서치 인스티튜트 Trail 유도를 위한 약리단
CN107427516B8 (zh) * 2015-01-30 2021-04-09 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017031101A1 (en) 2015-08-17 2017-02-23 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors
KR20170037260A (ko) 2015-09-25 2017-04-04 현대자동차주식회사 차량용 배터리 시스템 및 그 제어 방법
HRP20250207T1 (hr) 2016-01-29 2025-04-11 Oncoceutics, Inc. Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
SMT202100416T1 (it) 2016-03-02 2021-09-14 Eisai R&D Man Co Ltd Coniugati anticorpo-farmaco a base di eribulina e metodi di uso
KR20170110520A (ko) * 2016-03-23 2017-10-11 고려대학교 산학협력단 mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
JP2019513826A (ja) * 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
EP3496724B8 (en) * 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
AU2017353838A1 (en) 2016-11-03 2019-05-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer
WO2018129080A1 (en) * 2017-01-04 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Target genes in myc-driven neoplasia
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
IT201800004082A1 (it) * 2018-03-29 2019-09-29 Berlin Chemie Ag Composizioni farmaceutiche antitumorali per terapia combinata
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
MX2022006402A (es) 2019-11-28 2022-06-24 Inxmed Nanjing Co Ltd Uso de bi853520 en tratamiento contra el cancer.
EP4087840A4 (en) 2020-01-10 2024-01-10 Immuneering Corporation MEK INHIBITORS AND THEIR THERAPEUTIC USES
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
EP1487436A4 (en) 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
AU2009293545A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
US20120128732A1 (en) 2008-12-11 2012-05-24 Vuong Trieu Combinations and modes of administration of therapeutic agents and combination therapy
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
WO2012149546A2 (en) * 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
HRP20191181T1 (hr) 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
KR102611067B1 (ko) 2014-03-31 2023-12-06 더 스크립스 리서치 인스티튜트 Trail 유도를 위한 약리단

Also Published As

Publication number Publication date
IL275623A (en) 2020-08-31
CY1121735T1 (el) 2020-07-31
AU2019201896A1 (en) 2019-04-11
SG10201808496VA (en) 2018-10-30
CA3204801A1 (en) 2014-10-02
EP2968294A1 (en) 2016-01-20
NZ711948A (en) 2020-02-28
CA2905037A1 (en) 2014-10-02
ME03470B (me) 2020-01-20
CN119954807A (zh) 2025-05-09
BR112015023256A2 (pt) 2017-07-18
PT2968294T (pt) 2019-07-19
EP2968294B1 (en) 2019-05-01
RS59013B1 (sr) 2019-08-30
AU2014244117A1 (en) 2015-10-08
CN105530937A (zh) 2016-04-27
KR20220123335A (ko) 2022-09-06
JP2016512563A (ja) 2016-04-28
DK2968294T3 (da) 2019-07-15
JP2020172510A (ja) 2020-10-22
LT2968294T (lt) 2019-07-25
SI2968294T1 (sl) 2019-08-30
IL241452A0 (en) 2015-11-30
SMT201900384T1 (it) 2019-09-09
JP6446025B2 (ja) 2018-12-26
AU2020233606A1 (en) 2020-10-01
MX2015012636A (es) 2017-02-06
KR102438135B1 (ko) 2022-08-29
CA2905037C (en) 2023-08-29
ES2734568T3 (es) 2019-12-10
SG11201507247WA (en) 2015-10-29
NZ751509A (en) 2023-03-31
JP2018184411A (ja) 2018-11-22
MX2019013643A (es) 2020-02-03
HK1217653A1 (en) 2017-01-20
EP3572083A1 (en) 2019-11-27
US20140271540A1 (en) 2014-09-18
WO2014160130A1 (en) 2014-10-02
EA037937B1 (ru) 2021-06-09
US9265765B2 (en) 2016-02-23
AU2014244117B2 (en) 2018-12-20
EA201591715A1 (ru) 2016-07-29
KR20150136602A (ko) 2015-12-07
EP2968294A4 (en) 2016-10-19
PL2968294T3 (pl) 2019-10-31
HUE044238T2 (hu) 2019-10-28
IL241452B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
HRP20191181T1 (hr) 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
AU2020200692C1 (en) Heterocyclic amides useful as protein modulators
CN111712498B (zh) 作为prmt5抑制剂的取代的二环杂环化合物
JP6952695B2 (ja) インフルエンザウイルス複製の阻害剤、その適用方法および使用
DK2655375T3 (en) PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
CA2907502A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
CN106946876B (zh) 一种唑吡坦的制备方法
EP2863902A1 (en) Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors
KR20150023799A (ko) 치환 모르폴린을 포함한 신규 2,3-디하이드로-1H-이미다조[1,2-a]피리미딘-5-온 및 1,2,3,4-테트라하이드로피리미도[1,2-a]피리미딘-6-온 유도체, 그의 제조 방법 및 약학적 용도
AU2013282317A1 (en) Cyanoguanidines and their use as antiviral agents
CN103382195A (zh) 苯并吡喃查尔酮类化合物及其制备方法和用途
CN108239075B (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
Pan et al. Synthesis of 4-phenylthieno [2, 3-e][1, 2, 4] triazolo [4, 3-a] pyrimidine-5 (4H)-one derivatives and evaluation of their anti-inflammatory activity
Yong et al. Synthesis and preliminarily cytotoxicity to A549, HCT116 and MCF-7 cell lines of thieno [2, 3-d] pyrimidine derivatives containing isoxazole moiety
EP2714667B1 (en) Aminooxazole inhibitors of cyclin dependent kinases
CN116217566B (zh) 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
Keshipour et al. A novel one-pot isocyanide-based three-component reaction: synthesis of highly functionalized imidazo-chromen-4-ones
Guo et al. Design and synthesis of 1-substituted-β-carboline derivatives as potential anticancer agents
Prabha et al. Benzoquinoline amines–Key intermediates for the synthesis of angular and linear dinaphthonaphthyridines
Dobrowolski et al. A General Synthesis of 7-Phenyl-7, 13-dihydro-8H-benzo [6, 7] azepino [3, 2-c] quinolin-8-ones
Heppell et al. Synthesis, structures elucidation, DNA-PK, PI3K and antiplatelet activity of a series of novel 7-or 8-(N-substituted)-2-morpholino-quinazolines
Zoorob et al. Utility of cyclododecanone as synthon to synthesize fused heterocycles
Zhang et al. Microwave Irradiation for Accelerating Synthesis of Diarylimidizo [1, 5‐a] pyrimidine Based on Isoflavones
Roopan et al. Regioselective N-alkylation of (2-chloroquinolin-3-yl) methanol with N-heterocyclic compounds using the Mitsunobu reagent